• Skip to WISTA Sites
  • Skip to Main menu
  • Skip to Page content
WISTA Logo
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • Adlershof
  • Charlottenburg
  • South West
  • Marzahn
WISTA direkt
Search
  • de
  • en
  • WISTA Logo
  • About
    • Mission / Management
      • Company Profile
      • Team
      • Boards
      • Annual Reports
      • Invitations to tender
    • Sustainability / Diversity
    • Subsidiaries
    • Directions
  • News / Press
    • Overview
    • News
    • Events / Calendar
      • Diversity Conference Adlershof
    • Social Media Wall
    • Press
    • Magazine "Potenzial"
    • Adlershof Journal
    • Downloads
  • Services
    • All WISTA services
    • Business programmes
      • Adlershof Founder's Lab
    • Networks / Cooperations
    • Talent promotion / Recruiting
    • Event and Visitors Service
  • Projects
    • Focus Topics
    • Team Innovation
  • Sites
    • Overview
    • Technology Park Adlershof
    • Innovation Centre CHIC Charlottenburg
    • Innovation Campus FUBIC South West
    • CleanTech Business Park Marzahn
    • Business Office “Zukunftsorte”
  • Real Estate
    • Current Real Estate Offers
    • ST3AM Working Environments
    • Facility Management
  • Talents
    • Overview
    • WISTA as Employer
    • Jobs
    • Talent Promotion / Training
      • workhier! Young Academics Career Programme
      • STEM project SLE
      • Campus Club Adlershof
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • Adlershof
  • Charlottenburg
  • South West
  • Marzahn
WISTA direkt

News / Press

  • Overview
  • News
  • Events / Calendar
  • Social Media Wall
  • Press
  • Magazine "Potenzial"
  • Adlershof Journal
  • Downloads
  • Editorial Staff
  • WISTA
  • News / Press
21. February 2019

Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration

Harnessing the structural plethora of peptides to discover novel therapeutics

3B Pharmaceuticals GmbH (3BP), a private German biotechnology company announced a multi-year collaboration in the field of peptide-led drug discovery with Boehringer Ingelheim. Under the agreement, 3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets nominated by Boehringer Ingelheim. Hit compounds identified will be further optimized and jointly characterized by both companies. Dr. Ulrich Reineke, Managing Director of 3BP stated: “We are very pleased to substantially broaden our relationship with Boehringer Ingelheim and confident in adding significant value through our validated peptide hit discovery and medicinal chemistry capabilities.”

Financial terms of the collaboration were not disclosed. About 3B Pharmaceuticals is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3B Pharmaceuticals has built a technology platform extending from hit identification to early clinical development. 3BP was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Berlin, Bern and Basel. The company is owned by its founders and management.

More information

Dr. Jan Michel
Director Finance & Corporate Development
Tel.: +49 30 6392-4317
Fax: +49 30 6392-4316
e-mail: info(at)3b-pharma.com
www.3b-pharma.com

Biotechnology / Environment Business

Related News

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide

Related Institutions

  • 3B Pharmaceuticals GmbH
  • LinkedInshare0
  • Facebookshare0
  • WhatsAppshare0
  • E-Mail
  • © WISTA Management GmbH
  • Legal Notice
  • Privacy Policy
  • Contact
  • Career
  • Press
  • Social Media Guide
Member of:
Zukunftsorte Logo